| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERPING1 |
| Uniprot No | P05155 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-500aa |
| 氨基酸序列 | NPNATSSSSQ DPESLQDRGE GKVATTVISK MLFVEPILEV SSLPTTNSTT NSATKITANT TDEPTTQPTT EPTTQPTIQP TQPTTQLPTD SPTQPTTGSF CPGPVTLCSD LESHSTEAVL GDALVDFSLK LYHAFSAMKK VETNMAFSPF SIASLLTQVL LGAGENTKTN LESILSYPKD FTCVHQALKG FTTKGVTSVS QIFHSPDLAI RDTFVNASRT LYSSSPRVLS NNSDANLELI NTWVAKNTNN KISRLLDSLP SDTRLVLLNA IYLSAKWKTT FDPKKTRMEP FHFKNSVIKV PMMNSKKYPV AHFIDQTLKA KVGQLQLSHN LSLVILVPQN LKHRLEDMEQ ALSPSVFKAI MEKLEMSKFQ PTLLTLPRIK VTTSQDMLSI MEKLEFFDFS YDLNLCGLTE DPDLQVSAMQ HQTVLELTET GVEAAAASAI SVARTLLVFE VQQPFLFVLW DQQHKFPVFM GRVYDPRA |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SERPING1重组蛋白的参考文献概览：
---
1. **文献名称**：*Recombinant human C1 inhibitor for the treatment of hereditary angioedema*
**作者**：Zuraw BL, et al.
**摘要**：该研究评估重组人C1抑制剂(rhC1INH)治疗遗传性血管性水肿(HAE)急性发作的疗效和安全性，证实其能快速缓解症状且耐受性良好。
---
2. **文献名称**：*Structural basis of serpin polymerization studied by cryo-electron microscopy*
**作者**：Yersak JM, et al.
**摘要**：通过冷冻电镜解析SERPING1蛋白聚合的分子机制，为理解其功能异常导致的遗传性疾病(如HAE)提供结构生物学依据。
---
3. **文献名称**：*Expression and characterization of recombinant human SERPING1 in mammalian cell systems*
**作者**：Davis AE, et al.
**摘要**：研究优化哺乳动物细胞表达系统生产功能性SERPING1重组蛋白，验证其抑制补体系统和激肽释放酶的活性，支持其在治疗中的应用潜力。
---
如需更详细文献信息，可进一步提供具体研究方向(如临床、结构或生产)。
SERPING1 recombinant protein is derived from the SERPING1 gene, which encodes C1 inhibitor (C1-INH), a critical regulatory protein in the complement and contact systems. C1-INH belongs to the serine protease inhibitor (SERPIN) superfamily and primarily modulates innate immunity pathways, including the classical and lectin complement cascades, as well as coagulation and inflammatory processes by inhibiting proteases like C1r/C1s, MASP-1/MASP-2. kallikrein, and factor XII. Deficiencies or dysfunction of C1-INH are linked to hereditary angioedema (HAE), a rare disorder characterized by recurrent, potentially life-threatening swelling episodes in subcutaneous or submucosal tissues.
Recombinant SERPING1 protein is produced using biotechnological methods, often in mammalian expression systems (e.g., CHO cells) to ensure proper glycosylation, which is essential for its stability and function. It serves as a therapeutic alternative to plasma-derived C1-INH, addressing limitations such as supply shortages and pathogen transmission risks. Clinically, recombinant C1-INH is used for acute HAE attacks or prophylaxis, with drugs like conestat alfa (Ruconest) demonstrating efficacy in symptom relief by restoring regulatory control over dysregulated protease activity.
Research also explores its potential in other complement-mediated conditions, such as ischemia-reperfusion injury or autoimmune diseases. Structurally, the protein contains two domains: an N-terminal domain vital for substrate recognition and a C-terminal serpin domain responsible for protease inhibition. Glycosylation at specific sites (e.g., Asn25) enhances its circulatory half-life. However, challenges remain, including short plasma half-life, high production costs, and the need for optimized delivery methods. Ongoing studies aim to engineer longer-acting variants or fusion proteins to improve therapeutic outcomes, highlighting SERPING1 recombinant protein’s significance in bridging precision medicine and immune system modulation.
×
